Therapy Areas: Cardiovascular
Langhua Pharmaceutical passes US FDA's on-site inspection
31 March 2025 - Viva Biotech Holdings announced on Friday that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., successfully completed a cGMP on-site inspection by the US Food a...
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
27 March 2025 - Medical devices and health care company Abbott (NYSE:ABT) announced on Thursday that it has received CE Mark approval in Europe for its Volt Pulsed Field Ablation (PFA) System, designe...
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
26 March 2025 - Ionis Pharmaceuticals Inc (Nasdaq: IONS), a provider of RNA-targeted medicines, announced on Wednesday that it has expanded its partnership with biopharmaceutical company Sobi (STO: SO...
Sermonix Pharmaceuticals collaborates with Regor Therapeutics Group on development of new breast cancer treatments
25 March 2025 - Biopharmaceutical company Sermonix Pharmaceuticals announced on Monday a strategic collaboration with Regor Therapeutics Group, a clinical-stage biotechnology company, to optimise Rego...
BioCardia secures Japanese patent for Helix biotherapeutic delivery system
10 March 2025 - BioCardia Inc (Nasdaq:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced on Monday that the Japan Patent...
Doer Bio completes DR10624phase two clinical study enrolment
10 March 2025 - China-based clinical stage biopharmaceutical company Zhejiang Doer Biologics Co., Ltd. (Doer Bio) announced on Sunday that it has completed enrolment in the phase two clinical study of...